This suggests that hyperglycemia-induced upregulation of SHP-2 could have a critical role in monocyte dysfunction by promoting VEGF resistance to ultimately alter arteriogenesis in diabetic PAD patients. This evidence concerns the gene VEGFA and peripheral arterial disease.